Evaluation for Therapeutic Plasma Exchange for Immune Mediated Neurological Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to Evaluation of Therapeutic Plasma Exchange for Immune-Mediated Neurological Diseases in a Sample of Egyptian Patients: An Experience at Al-Azhar University Hospitals, including evaluating clinical response rates and functional improvement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy

NCT00268788

Multifocal Motor Neuropathy

COMPLETED PHASE2

Therapeutic Plasma Exchange in MG

NCT01927692

Myasthenia Gravis

COMPLETED

Immunoglobulin Dosage and Administration Form in CIDP and MMN

NCT02111590

Chronic Inflammatory Demyelinating Polyneuropathy Multifocal Motor Neuropathy Hemolytic Anemia

COMPLETED

Study of CIDP Patients During IVIG Treatment

NCT00305266

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

COMPLETED

Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07154524

Chronic Inflammatory Demyelinating Polyneuropathy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Therapeutic plasma exchange (TPE) is recommended as Class I therapies by the American Society for Apheresis (ASFA) guidelines and are widely used as first-line therapies for the treatment of acute neuroimmune diseases , TPE is generally well tolerated, with minor complications occurring in about 20-30% of patients ,(ASFA) publishes regular guidelines on the indications for TPE. Studies performed over the last three decades showed that myasthenia gravis (MG), Guillain-Barre syndromé (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) were the most frequently cited indications for TPE followed by multiple sclerosis (MS) , The aims of this research to evaluate therapeutic plasma exchange for immune-mediated neurological diseases in a sample of Egyptian patients, including evaluating clinical response rates and functional improvement

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurological Autoimmune Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. All neurological patients irrespective of age who will undergo TPE. 2.All new and relapse cases that meet the ASFA guidelines and where TPE is the first and/or second line of therapy

Exclusion Criteria

* 1\. Individuals with contraindications to therapeutic plasma exchange, such as hemodynamic unstable, hypocalcaemia, allergy to fresh frozen plasma or albumin.

2.Patients who will undergo fewer than five cycles of TPE and not complete the procedure.

3.Patients with non-neurological disorders.

Eligible Sex

ALL

Accepts Healthy Volunteers

No